SCHEMBL563630

SCHEMBL563630

[CH2]C1(O)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HPGD P15428 1/20 0.45
EPHX2 P34913 1/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
TSHR P16473 2/20 0.40
ALOX15 P16050 1/20 0.40
ATM Q13315 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18049862 0.87 USP2 (0.55) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL78071 0.83 USP2 (0.55) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL26007598 0.81 USP2 (0.53) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL346995 0.81 USP2 (0.56) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL3436829 0.81 USP2 (0.56) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL3713607 0.81 USP2 (0.49) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL24672559 0.80 USP2 (0.51) USP2SMN1; SMN2HPGDEPHX2RECQL
Methane SCHEMBL27676530 0.80 USP2 (0.51) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL4298314 0.80 USP2 (0.51) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL18294 0.80 USP2 (0.69) USP2SMN1; SMN2HPGDEPHX2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115109032-B Quinoline derivative and application thereof in medicine 成都百裕制药股份有限公司 2023-09-05 CN disclosed
CN-115109032-A Quinoline derivative and application thereof in medicine 成都百裕制药股份有限公司 2022-09-27 CN disclosed
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed
WO-2006038923-A2 ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 USP2 4272/4885SMN1; SMN2 2868/4885HPGD 61/4885
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 USP2 3949/4885SMN1; SMN2 3309/4885HPGD 449/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 USP2 4289/4885SMN1; SMN2 2925/4885HPGD 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.